We were delighted to speak with Prof. Amy S. Paller (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) about the results from the phase 3, LIBERTY AD PEDS trial (NCT03345914). This double-blind, 16-week study investigated duplimuab in children with atopic dermatitis.
Her abstract entitled ‘Dupilumab Provides Clinically Meaningful Improvement in Atopic Dermatitis (AD) Signs, Symptoms, and Quality of Life in Children With Severe AD: Results From the LIBERTY AD PEDS Phase 3 Clinical Trial’ was presented at the AAD VMX, 23-25 April 2021.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.
Questions
- What were the aims and design of the LIBERTY AD PEDS study? (0:24)
- What were the primary and key secondary endpoints of this study? (1:22)
- How well were these endpoints met? (2:10)
- Where do you see dupilumab sitting in the future treatment paradigm for atopic dermatitis in children? (4:12)
Disclosures: Prof. Amy Paller has acted as a consultant with honorarium for AbbVie, Abeona, Alcimed, Almirall, Amagma, Anaptysbio, Arena, Azitra, BiomX, Boehringer Ingelheim, Castle Biosciences, Catawba, Dermira, Eli Lilly, Exicure, Forte, Galderma, Kamari, Leo, Lifemax, NAOS, Novartis, Pfizer, Phoenix, Pierre Fabre, Sanofi/Genzyme, Seanergy, Trifecta and UCB; and an investigator (to institution) for AbbVie, Eli Lilly, Janssen, Regeneron, Incyte and UCB
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the AAD VMX 2021.
